Compare ONCH & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONCH | AVTX |
|---|---|---|
| Founded | 2024 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.2M | 248.3M |
| IPO Year | N/A | 2015 |
| Metric | ONCH | AVTX |
|---|---|---|
| Price | $10.21 | $17.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 93.0K | ★ 407.3K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $10.16 | $3.39 |
| 52 Week High | $10.63 | $20.72 |
| Indicator | ONCH | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 59.88 |
| Support Level | $10.17 | $17.18 |
| Resistance Level | $10.26 | $19.35 |
| Average True Range (ATR) | 0.03 | 1.30 |
| MACD | 0.00 | 0.43 |
| Stochastic Oscillator | 44.44 | 90.27 |
1RT Acquisition Corp is a blank check company.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).